April 2010
Volume 51, Issue 13
ARVO Annual Meeting Abstract  |   April 2010
Efficacy of Mycophenolate Mofetil, Methotrexat and Cyclosporine for the Treatment of Uveitis
Author Affiliations & Notes
  • J. Schlotter
    University Eye Hospital, Freiburg, Germany
  • D. Boehringer
    University Eye Hospital, Freiburg, Germany
  • T. Ness
    University Eye Hospital, University of Freiburg, Freiburg, Germany
  • Footnotes
    Commercial Relationships  J. Schlotter, None; D. Boehringer, None; T. Ness, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 5267. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      J. Schlotter, D. Boehringer, T. Ness; Efficacy of Mycophenolate Mofetil, Methotrexat and Cyclosporine for the Treatment of Uveitis. Invest. Ophthalmol. Vis. Sci. 2010;51(13):5267.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : To evaluate the efficacy and tolerance of mycophenolate mofetil (MMF), methotrexate (MTX), and cyclosporine as first immunosuppressive agent for the treatment of non-infectious uveitis.

Methods: : In this retrospective case study the records of 544 patients with uveitis treated at a single academic referral center were reviewed. These data were analyzed in accordance with SUN (Standardization of Uveitis Nomenclature) recommendations. All patients included had primarily been treated with systemic steroids and reduction had failed prior to the immunosuppressive therapy. The main outcome parameters of the different immunosuppressive agents were: time of relapse free survival (a concomitant prednisolone dosage < 5 mg was allowed) and rate of discontinuation because of side effects.

Results: : 137 patients were included in the study. The patients suffered from anterior, posterior or panuveitis. The mean follow-up was 2 years. The initial therapy with systemic corticosteroids was effective in about 75% of the patients. Therefore only about 25% of these patients needed an immunosuppressive therapy. There was no statistically significant difference between the three immunossuppresants. With all substances about two third of the patients achieved a prednisolone dosage of 5 mg or less without any relapse. The rate of intolerance due to side effects was low in all groups.

Conclusions: : The primary efficacy of cyclosporine, MTX, and MMF was comparable. Since there is no difference in therapy outcome, the decision for one substance should be made with respect to the expected side effects in relation to the specific condition of the patient.

Keywords: uveitis-clinical/animal model • immunomodulation/immunoregulation • clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.